Improvements in molecular analysis open new prospects for personalized therapy, targeting HER2, Claudine, FGFR, and other changes in molecular-matched therapy can significantly improve clinical outcomes in patients with advanced gastric cancer [19].Currently, inhibitors targeting PARP have demonstrated promising results in the treatment of various malignancies, including ovarian cancer [20], prostate cancer [21], endometrial cancer [22], among others. This evidence concerns the gene ERBB2 and ovarian carcinoma.